Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chordomas Clear all
Active, not recruiting Phase 2 Interventional

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

NCT05041127
View directory record Official record
Conditions
Chordoma, Metastatic Chordoma, Unresectable Chordoma
Interventions
Cetuximab, Questionnaire Administration
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma, Wilms Tumor
Interventions
Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 1Phase 2 Interventional

Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine

NCT00592748
View directory record Official record
Conditions
Chordoma, Chondrosarcoma
Interventions
Charged Particle Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

NCT03623854
View directory record Official record
Conditions
Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
Interventions
Nivolumab, Relatlimab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 5:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT05286801
View directory record Official record
Conditions
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Tiragolumab, X-Ray Imaging
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas

NCT00713037
View directory record Official record
Conditions
Chordoma
Interventions
Fluoromisonidazole-PET/CT
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Jul 22, 2026, 5:59 PM EDT
Completed No phase listed Observational

Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families

NCT00341627
View directory record Official record
Conditions
Chordoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 110 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
2
States / cities
Iowa City, Iowa • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Jul 22, 2026, 5:59 PM EDT
Completed No phase listed Observational

Chordoma Family Study

NCT00410670
View directory record Official record
Conditions
Chordoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 22, 2026, 5:59 PM EDT
Available No phase listed Expanded access

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

NCT04091295
View directory record Official record
Conditions
Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast, Single Patient IND for Glioblastoma, Ovarian Carcinoma, Non-small Cell Lung Cancer , Prostate Cancer
Interventions
DNG64-CAR-V
Drug
Lead sponsor
Aveni Foundation
Other
Eligibility
12 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Active, not recruiting No phase listed Observational

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

NCT01200680
View directory record Official record
Conditions
Genes, Sporadic Chordoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 99 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Trial of Dasatinib in Advanced Sarcomas

NCT00464620
View directory record Official record
Conditions
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma, Gastrointestinal Stromal Tumor (GIST)
Interventions
Dasatinib
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
13 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Jul 22, 2026, 5:59 PM EDT
Active, not recruiting Not applicable Interventional

High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull

NCT01346124
View directory record Official record
Conditions
Chordoma of Spine, Chordoma of Sacrum, Chordoma of Base of Skull, Chondrosarcoma of the Spine, Chondrosarcoma of the Sacrum
Interventions
High Dose Intensity Modulated Proton Radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01924689
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
Clostridium novyi-NT spores
Biological
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
St Louis, Missouri • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Jul 22, 2026, 5:59 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753
View directory record Official record
Conditions
Synovial Sarcoma, Soft Tissue Sarcoma
Interventions
CFT8634
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 22, 2026, 5:59 PM EDT
Terminated Phase 1 Interventional

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02936102
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions
FAZ053, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 22, 2026, 5:59 PM EDT
Completed No phase listed Observational

Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

NCT01567046
View directory record Official record
Conditions
Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Chordoma, Desmoid Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Recurrent Childhood Soft Tissue Sarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 22, 2026, 5:59 PM EDT
Terminated Phase 1 Interventional

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

NCT00931931
View directory record Official record
Conditions
Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma, Neuroblastoma, Wilms Tumor, Malignant Peripheral Nerve Sheath Tumor, Clival Chordoma, Non-CNS Solid Tumors
Interventions
HSV1716
Biological
Lead sponsor
Timothy Cripe
Other
Eligibility
7 Years to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 22, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

NCT03886311
View directory record Official record
Conditions
Sarcoma
Interventions
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

NCT01682746
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin (porfimer sodium) & photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
6 Months to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Jul 22, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Proton Radiation for Chordomas and Chondrosarcomas

NCT01449149
View directory record Official record
Conditions
Chordomas, Chondrosarcomas
Interventions
Proton Therapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 5:59 PM EDT
Not listed Phase 1 Interventional

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

NCT01175109
View directory record Official record
Conditions
Chordoma
Interventions
Imatinib + LBH589
Drug
Lead sponsor
Deric M Park MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Jul 22, 2026, 5:59 PM EDT